Top Markets
Coin of the day
Gyre Therapeutics, Inc. Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

GYRE
Rang in Aktien #11143
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering,... Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Aktienkurs
$6.61
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$736.94M
Veränderung (1 Tag)
-1.05%
Veränderung (1 Jahr)
-14.60%
Land
US
Handel Gyre Therapeutics, Inc. (GYRE)

Kategorie

Kursverlauf für Gyre Therapeutics, Inc. (GYRE)
Höchster Schlusskurs: $6.72 am 2026-08-01

Niedrigster Schlusskurs: $12.50K am 2006-04-01
Kursverlauf der Aktie von Gyre Therapeutics, Inc. von 2006 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -3.27%
2025 -32.25%
2024 -52.32%
2023 202.08%
2022 -50.65%
2021 -83.58%
2020 8.07%
2019 -33.68%
2018 -12.06%
2017 -1.82%
2016 -72.82%
2015 -85.70%
2014 -47.12%
2013 3.59%
2012 -31.84%
2011 -72.71%
2010 10.88%
2009 733.78%
2008 -69.18%
2007 13.36%
2006 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH